901 Gateway Boulevard
South San Francisco
About Theravance Biopharma
Theravance Biopharma is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease (COPD). Our neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase (JAK) inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (the Closed Triple), currently in development for the treatment of COPD and asthma.
114 articles with Theravance Biopharma
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Healthcare Conference on Thursday, May 17, 2018, at 10:40 a.m. PT. The conference will be held May 15 - 17 at the Encore Wynn in Las Vegas.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
Plenty of exciting news in the research world. Here’s a look at some of the top stories.
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
Data from TOUR™ Observational Patient Registry Highlights Positive Clinical Response Rates in Elderly and Obese Patients Additional VIBATIV Study Results Demonstrate Greater in vitro Potency than Competitor Antibiotics Against Difficult-to-Treat Staphylococcus aureus Pathogens including Challenging Multidrug Resistant (MDR) MRSA Isolates
Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection.
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
If this latest submission is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy.
J&J inked a global collaboration deal with Theravance Biopharma to develop a drug for IBD.
Theravance Biopharma and Mylan Announce FDA Acceptance of NDA for Revefenacin (TD-4208) in Adults With COPD
The FDA has assigned a PDUFA target action date of November 13, 2018, and indicated that it does not currently plan to convene an advisory committee meeting to discuss the NDA.
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta
If this sNDA is approved, the labeled indication for Trelegy Ellipta would include a wider population of patients with COPD who are at risk of an exacerbation and require triple therapy.
Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD
Trelegy Ellipta is a product in which Theravance Biopharma has an economic interest in future payments that may be made by Glaxo or one of its affiliates pursuant to its agreements with Innoviva.
Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults With COPD
The NDA is supported by the companies' Phase III program for revefenacin, which consisted of two replicate pivotal Phase III efficacy studies and a 12-month, open-label, active comparator safety study.
Theravance Biopharma Reports Positive New Data From Multiple Studies Of VIBATIV (Telavancin) At IDWeek 2017
Theravance Biopharma Highlights Positive Headline Results From IMPACT Study Of Trelegy Ellipta Announced By GlaxoSmithKline And Innoviva Inc.
Theravance Biopharma Highlights Approval Of Trelegy Ellipta (Closed Triple) As The First Once-Daily Single Inhaler Triple Therapy For The Treatment Of Appropriate Patients With COPD In The U.S.
Theravance Biopharma Highlights GlaxoSmithKline And Innovia's Receipt Of Positive Opinion From CHMP In Europe For Trelegy Ellipta (Closed Triple)
Theravance Biopharma Reports Encouraging Data From First Cohort Of Patients In Phase Ib Clinical Trial Of TD-1473 In Ulcerative Colitis
Theravance Biopharma Announces Positive Top-Line Results From Phase IIb Study Of Velusetrag (TD-5108) In Patients With Gastroparesis
Theravance Biopharma To Report Second Quarter 2017 Financial Results And Business Update On August 8, 2017